Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$30.55M$30.55M−8.7% vs Q2 2017 Net Income$10.09M$10.09M−11.2% vs Q2 2017 EPS Diluted$0.68$0.68−10.5% vs Q2 2017 Gross Profit$22,390,000+1.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$4,471,000−28.7% Free Cash Flowderived$3,731,000−7.4% Margins · derivedGross margin73.3%+7.5 pt vs Q2 2017
Operating margin36.8%−16.2 pt vs Q2 2017
Net margin33.0%−0.9 pt vs Q2 2017
ended Jun 30, 2018 · filed Jul 31, 2018 · 31 d after period end